indexmarketsresearchFebruary 13, 2021
The advanced research tools study Global
Metformin Hydrochloride Market report provides statistical data presented in an organized format including charts, graphs, tables, and illustrations to easily provide a detailed understanding of the Metformin Hydrochloride market. The report encompasses a comprehensive analysis of the Metformin Hydrochloride market and provides key insights into the current and emerging trends, market drivers, and market insights from industry experts. Global Metformin Hydrochloride market report is a well-conceived and accurately delivered market intelligence report depicting crucial elements across the current and historic market states that play a crucial role in influencing unfaltering forecast and predictions. The report also offers a detailed abstract of the statistics, market valuation, and revenue forecast, which in addition underlines the status of the competitive spectrum and expansion strategies adopted by
How PMs aim for impact through investment in cancer treatment citywireselector.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citywireselector.com Daily Mail and Mail on Sunday newspapers.
Published: Feb 01, 2021
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Constantine Kreatsoulas, PhD has joined Circle Pharma, Inc. as its Vice President of Research Informatics and Computational Chemistry.
Dr. Kreatsoulas joins Circle from GlaxoSmithKline (GSK) where he was the Head of US Molecular Design and Interim Head of Computational Toxicology. His responsibilities at GSK included leading structure-based drug design (SBDD) teams and the development of informatics tools for quantitative experimental data analytics and drug hazard identification. Previously he was a Research Fellow at Merck & Co., Inc., where he focused on SBDD, molecular modeling, machine learning, and small molecule safety assessment and a postdoctoral fellow at Bristol-Meyers Squibb focused on machine learning in predictive toxicology. Dr. Kreatsoulas was awarded a doctorate in chemistry from Princeton University, holds a master’s degree in regulatory affairs and quality assurance from Temple Un
E-Mail
(Boston) Atrial fibrillation (AF) is associated with a higher risk of complications including ischemic stroke, cognitive decline, heart failure, myocardial infarction and death. AF frequently is undetected until complications such as stroke or heart failure occur.
While the public and clinicians have an intense interest in detecting AF earlier, the most appropriate strategies to detect undiagnosed AF and medical prognosis and therapeutic implications of AF detected by screening are uncertain.
A new report led by Boston University School of Medicine (BUSM) researcher Emelia J. Benjamin, MD, ScM, builds upon a recently conducted National Heart, Lung, and Blood Institute s virtual workshop that focused on identifying key research priorities related to AF screening.
Plenty of private longevity research companies are working on innovative studies aimed at diseases associated with the aging process, including cardiovascular disease, type 2 diabetes and various cancers. If they do go public one day, investors who have them on their radar already will be ahead of the game.
Here’s a short list of some of the top private longevity research companies making headlines today.
1. Sanumed
Sanumed is first on our list of longevity research companies. Based in San Diego, California, the company develops small-molecule, tissue-level therapeutic drugs aimed at treating numerous degenerative diseases, as well as many forms of cancer.